Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations

The Prostate ◽  
2021 ◽  
Author(s):  
Alexandra O. Sokolova ◽  
Catherine H. Marshall ◽  
Rebeca Lozano ◽  
Roman Gulati ◽  
Elisa M. Ledet ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Brca2 Mutations ◽  
Systemic Therapies

scholarly journals Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry

2019 ◽  
Vol 22 (3) ◽  
pp. 420-427 ◽  
Author(s):  
Edoardo Francini ◽  
Kathryn P. Gray ◽  
Grace K. Shaw ◽  
Carolyn P. Evan ◽  
Anis A. Hamid ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Systemic Therapies

Impact of treatment sequence on the outcomes of metastatic castration resistant prostate cancer patients (mCRPC) with germline BRCA2 mutations: A subanalysis of the PROREPAIR-B study.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 5071-5071
Author(s):  
Nuria Romero-Laorden ◽  
Elena Castro ◽  
Ana Medina ◽  
David Lorente ◽  
Enrique González-Billalabeitia ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Treatment Sequence ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Brca2 Mutations

Therapy Management of Metastatic Prostate Carcinoma in General Practice

2019 ◽  
pp. 12-15
Author(s):  
Alexander Meisel
Keyword(s):  
Prostate Cancer ◽  
Advanced Prostate Cancer ◽  
Treatment Strategies ◽  
Castration Resistant Prostate Cancer ◽  
Continuous Therapy ◽  
Castration Resistant ◽  
Literature Overview ◽  
Metastatic Prostate Carcinoma ◽  
Insight Into ◽  
Systemic Therapies

ABSTRACT In general, advanced prostate cancer is initially treated with androgen deprivation therapy (ADT). Despite high response rates to this treatment, the response is not durable and most of the patients eventually develop metastatic castration-resistant prostate cancer (mCRPC). The treatment strategies for mCRPC usually include a combination of different approaches, such as hormone therapy, chemotherapy, or radiation. Here, we discuss the case of a 78-year old patient with advanced prostate cancer who developed mCRPC after 4 years of continuous therapy with ADT. The patient was subsequently treated with analgesic radiotherapy, followed by chemotherapy, including docetaxel and cabazitaxel. The patient responded well to the treatment, with acceptable treatment-related toxicity. Three years later, however, the disease progressed, and the patient received anti-hormonal therapy with enzalutamide. In conclusion, this case report discusses the different therapy selections and outcomes. Finally, a literature overview offers a comprehensive insight into the current systemic therapies for mCRPC.

scholarly journals Impact of new systemic therapies in overall survival in non-metastatic castration resistant prostate cancer: systematic review and meta-analysis

2021 ◽  
Author(s):  
Alejo Rodriguez-Vida ◽  
Andrés Rodríguez-Alonso ◽  
Eduardo Useros-Rodríguez ◽  
Fernando Lopez-Campos ◽  
Oscar Amor-Carro ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Overall Survival ◽  
Meta Analysis ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Systemic Therapies

scholarly journals Sequencing Systemic Therapies in Metastatic Castration-Resistant Prostate Cancer

2013 ◽  
Vol 20 (3) ◽  
pp. 181-187 ◽  
Author(s):  
Jane Jijun Liu ◽  
Jingsong Zhang
Keyword(s):  
Prostate Cancer ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Systemic Therapies

scholarly journals Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Panagiotis J. Vlachostergios ◽  
Muhammad Junaid Niaz ◽  
Michael Sun ◽  
Seyed Ali Mosallaie ◽  
Charlene Thomas ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Emission Computed Tomography ◽  
Prostate Specific Membrane Antigen ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Pet Ct ◽  
Specific Membrane ◽  
Psma Expression ◽  
Systemic Therapies

BackgroundProstate-specific membrane antigen (PSMA) imaging has been suggested as highly sensitive modality for detection of metastases in patients with biochemically recurrent or advanced prostate cancer (PCa). PSMA expression is associated with grade and stage and has a relationship with androgen receptor signaling. The aim of this study was to evaluate the prognostic utility of radiographic PSMA expression in men with metastatic castration-resistant prostate cancer (mCRPC).MethodsPatients with mCRPC and available baseline PSMA imaging were studied. Images by planar/single-photon emission computed tomography (SPECT) or positron emission tomography (PET)/CT were reviewed. Planar/SPECT images were scored semi-quantitatively and PET/CT scored quantitatively with comparison of tumor uptake to liver uptake on a scale of 0–4 in order to determine an imaging score (IS). The IS (high: 2–4 versus low: 0–1), subsequent receipt of life-prolonging systemic therapies (taxane chemotherapy, potent androgen receptor pathway inhibitors, sipuleucel-T, and radium-223), and the CALGB prognostic risk stratification of patients were analyzed according to overall survival (OS) in univariate and multivariate Cox’s proportional hazards models.ResultsHigh PSMA expression (IS 2–4) was found in 179 (75.21%) patients, and 59 (24.79%) patients had low PSMA uptake. The median OS of the entire cohort was 16.8 (95%CI: 14.9–19.3) months. Patients with a high IS had a significantly shorter OS of 15.8 (95%CI 13.0–18.1) months compared to those with low expression [22.7 (95%CI: 17.7–30.7) months, p = 0.002]. After accounting for use of life-prolonging therapies (p<0.001) and CALGB prognostic groups (p = 0.001), high PSMA IS emerged as an independent prognostic factor for OS [HR(95%CI): 1.7 (1.2–2.2); p = 0.003].ConclusionPresence of high radiographic PSMA expression on SPECT or PET/CT may portend a poor prognosis in patients with mCRPC treated with standard systemic therapies. This provides implications for therapeutic targeting of PSMA-avid disease as a means to improve outcomes.

Sign in / Sign up

Export Citation Format

Share Document